Takeda inches closer to take over Shire

Takeda Pharmaceutical announced onTuesday that it has received US approval for its $62bn acquisition of London-listed Shire. The Japanese company is still awaiting approval from regulators in China and the EU, as well as from shareholders of both firms.

CEO Christophe Weber is trying to persuade investors about the deal's cost-saving merits, but concerns of the financial burden the combined company will carry has already influence Takeda's stock price. If finalised, the deal would help the Japanese enter the list of global top 10 drugmakers.

Similar articles

  • Airbus presents A220, rebranded Bombardier

    Airbus presents A220, rebranded Bombardier

    Airbus unveiled last Tuesday its newest jet, the A220, which is actually a rebranded Bombardier's CSeries passenger plane, news wires reported. The new 110-130-seat jet is set to further broaden its battle with Boeing on the small passenger jets field. The rebranded plane will be slotted just under its longstanding A300 portfolio which stretches from the 124-seat A319 to the 544-seat A380.